MediGene AG - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 115

MediGene AG – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “MediGene AG - Product Pipeline Review - H2 2011” provides data on the MediGene AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MediGene AG’s corporate website, SEC filings, investor presentations and featured press releases, both from MediGene AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MediGene AG - Brief MediGene AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MediGene AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MediGene AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MediGene AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MediGene AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MediGene AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MediGene AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MediGene AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MediGene AG and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of MediGene AG; MediGene AG - Key Therapeutics; MediGene AG - Pipeline Overview and Promising Molecules; MediGene AG - News; MediGene AG - Latest Updates; MediGene AG - Pipeline; MediGene AG - Discontinued/Dormant Projects

List of Tables
List of Figures
MediGene AG Snapshot
MediGene AG Overview
Key Information
Key Facts
MediGene AG – Research and Development Overview
Key Therapeutic Areas
MediGene AG – Pipeline Review
Pipeline Products by Stage of Development
MediGene AG – Pipeline Products Glance
MediGene AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MediGene AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
MediGene AG – Drug Profiles
Adeno-Associated Virus-Like Particles
Product Description
Mechanism of Action
R&D Progress
EndoTAG-1
Product Description
Mechanism of Action
R&D Progress
EndoTAG-1 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Etomoxir
Product Description
Mechanism of Action
R&D Progress
G207
Product Description
Mechanism of Action
R&D Progress
L1 Monoclonal Antibody
Product Description
Mechanism of Action
R&D Progress
NV1020
Product Description
Mechanism of Action
R&D Progress
RhuDex
Product Description
Mechanism of Action
R&D Progress
MediGene AG – Pipeline Analysis
MediGene AG – Pipeline Products by Therapeutic Class
MediGene AG - Pipeline Products By Target
MediGene AG – Pipeline Products by Route of Administration
MediGene AG – Pipeline Products by Molecule Type
MediGene AG – Recent Pipeline Updates
MediGene AG - Dormant Projects
MediGene AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CVLP-Vaccine
Etomoxir
MediGene AG – Company Statement
MediGene AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 29, 2006: MediGene AG Successfully Closes Acquisition of UK-based Avidex Ltd.
Nov 28, 2007: MediGene And Celltrion Announce Co-Development Of Anti-L1 Monoclonal Antibody Therapeutic For Treating Cancer
Oct 28, 2011: MediGene Receives Authorization For Clinical Formulation Study Of RhuDex
Mar 25, 2003: MediGene Discontinues Development Of CVLP Tumor Vaccine
Jan 25, 2008: MediGene To Present Recent Data Obtained In A Clinical Trial Of Oncolytic Virus NV1020 On The Occasion Of The ASCO GI Symposium
Aug 24, 2005: Medigene Initiates Clinical Phase II - Trial Of EndoTAG-1 In Advanced Pancreatic Cancer
Jun 24, 2010: MediGene Announces Study Results On EndoTAG-1 From Phase II Trial For Treatment Of Triple Receptor-Negative Breast Cancer
Jun 24, 2008: RhuDex Achieves Positive Results in Clinical Phase IIa Trial
Jan 23, 2007: RhuDex Enters Clinical Phase IIa Trial in Rheumatoid Arthritis
Dec 21, 2006: MediGene: Positive Phase II Interim Results In Clinical Trial Of EndoTAG-1 Against Pancreatic Cancer
Mar 21, 2001: MediGene AG's NV1020 Shows Good progress in Phase 1 study To Treat Colorectal Cancer Metastatic To The Liver
Oct 20, 2008: Medigene Reports Positive Final Results From EndoTAG-1 Phase II Study In Pancreatic Cancer
Oct 17, 2008: Active Biotech's Partner MediGene Announces Information Regarding RhuDex To Be Examined In Further Laboratory Tests
Jul 17, 2008: MediGene Exercises Option For Anti-L1 Monoclonal Antibody And Continues Collaboration With DKFZ (German Cancer Research Center)
Sep 16, 2010: MediGene Receives Additional US Patent Protection For EndoTAG-1
Sep 15, 2006: MediGene Finds Dose Trial Of Oncolytic Virus NV1020 For The Treatment Of Liver Metastases
Jul 15, 2008: MediGene Publishes Update On RhuDex Incident
Oct 11, 2006: European Regulatory Authority Recommends Orphan Drug Designation For MediGene's Drug Candidate EndoTAG-1
Oct 09, 2009: MediGene Successfully Completes Patient Recruitment Into EndoTAG-1 Phase II Breast Cancer Trial
Oct 09, 2009: MediGene Successfully Completes Patient Recruitment Into EndoTAG-1 Phase II Breast Cancer Trial
Oct 09, 2003: MediGene Acquires Patents On Anti-Cancer Drugs G207 And NV1020 Which Are Under Development
Sep 09, 2008: New Clinical Data For EndoTAG(TM)-1 To Be Presented At 33rd ESMO Congress In Stockholm
May 09, 2005: Active Biotech Initiates Phase I Clinical Trial Of RhuDex
Mar 09, 2006: Avidex and Active Biotech Concludes Phase I Clinical Trials Of RhuDex
Jul 08, 2008: MediGene Puts Clinical Phase I Study With RhuDex On Hold
Aug 07, 2009: Active Biotech Presents Information Regarding The Candidate Drug RhuDex(TM)
Oct 05, 2009: Active Biotech's RhuDex Clinical Development To Continue Following Feedback From Regulatory Authorities
Oct 05, 2009: RhuDex(TM) Clinical Development To Continue Following Feedback From Regulatory Authorities
Sep 05, 2007: MediGene AG Completes Patient Recruitment For The Clinical Phase I/II Trial Of NV1020
Jan 05, 2011: CDC Recommends Nycomed's VEREGEN As Therapeutic Option For EGWs In 2010 STD Treatment Guidelines
Mar 04, 2010: MediGene's Veregen Launched By Solvay In Germany
Nov 03, 2004: MediGene AG Concludes License Agreement For The Further Optimization of Cancer-Killing HSV Viruses Including NV1020
Oct 02, 2007: MediGene Obtains US Patent On RhuDex
Sep 02, 2004: MediGene Initiates Clinical Phase I/II Trial Of Cancer-Killing Virus NV1020 For The Treatment Of Liver Metastases
Financial Deals Landscape
MediGene AG, Deals Summary
MediGene AG, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
MediGene Acquires Oracea From CollaGenex
MediGene Acquires Assets From Munich Biotech
Partnerships
MediGene Enters Into Co-Development Agreement With Johns Hopkins University
MediGene To Enter Into Co-Development Agreement For EndoTAG-1
MediGene Enters Into An Distribution Agreement With Juste
MediGene Enters Into Co-Development Agreement With Celltrion
MediGene Extends Collaboration Agreement With German Cancer Research Center
MediGene Enters Into Research Agreement With Juvenile Diabetes Research
MediGene Enters Into Research Agreement With Sanofi Pasteur
MediGene Enters Into Collaboration With German Cancer Research Center
MediGene Enters Into Co-Marketing Agreement With Bradley Pharmaceuticals
MediGene Enters Into Agreement With Yamanouchi
Licensing Agreements
MediGene Enters Into Licensing Agreement With Virionics
MediGene Enters Into Licensing Agreement With Astellas Pharma
MediGene Enters Into Licensing Agreement With Pharmanova For Veregen
MediGene Enters Into Licensing Agreement With Syncore Biotechnology For Veregen
MediGene Enters Into Licensing Agreement With Triton Pharma For Veregen
MediGene Enters Into Licensing Agreement With Will-Pharma For Veregen
MediGene Enters Into Licensing Agreement With Pierre Fabre For Veregen
MediGene Enters Into Licensing Agreement With Laboratoires Expanscience
MediGene Enters Into License Agreement With GC-Rise Pharmaceutical
MediGene Enters Into Licensing Agreement With JS Bio Pharm
MediGene Signs Licensing Agreement With Meditrina Pharmaceuticals
MediGene Enters Into Licensing Agreement With Teva Pharmaceutical
MediGene Enters Into Licensing Agreement With Solvay Pharmaceuticals
MediGene Enters Into Licensing Agreement With German Cancer Research Center
MediGene Enters Into Licensing Agreement With Glaxo Group
Avidex Enters Into Licensing Agreement With Active Biotech
MediGene Enters Into Licensing Agreement With The University Of British Columbia
MediGene Enters Into Licensing Agreement With The University Of Chicago
Equity Offering
MediGene Completes Private Placement Of $3 Million
MediGene Completes Private Placement Of $21 Million
MediGene Completes Private Placement Of $16 Million
MediGene Completes Private Placement Of $19 Million
MediGene Completes Private Placement Of $27 Million
MediGene Completes Private Placement Of $9 Million
MediGene Completes Private Placement Of $9 Million
Debt Offering
MediGene Completes Private Placement Of 4% Convertible Bonds For $2 Million
Asset Transactions
MediGene Completes Sale Of European Rights For Eligard To Astellas
Catherex Acquires Oncolytic Herpes Simplex Viruses Program From MediGene
Galderma Laboratories Acquires Oracea Rights From MediGene
Acquisition
MediGene Acquires Avidex
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
MediGene AG – Pipeline by Therapy Area and Indication, H2 2011
MediGene AG – Pipeline by Stage of Development, H2 2011
MediGene AG - Phase II, H2 2011
MediGene AG - Phase I, H2 2011
MediGene AG - Pipeline By Therapeutic Class, H2 2011
MediGene AG - Pipeline By Target, H2 2011
MediGene AG – Pipeline By Route of Administration, H2 2011
MediGene AG – Pipeline By Molecule Type, H2 2011
MediGene AG – Recent Pipeline Updates, H2 2011
MediGene AG - Dormant Developmental Projects, 2010
MediGene AG - Discontinued Pipeline Products, 2010
MediGene AG, Subsidiaries
MediGene AG, Deals Summary
MediGene Acquires Oracea From CollaGenex
MediGene Acquires Assets From Munich Biotech
MediGene Enters Into Co-Development Agreement With Johns Hopkins University
MediGene To Enter Into Co-Development Agreement For EndoTAG-1
MediGene Enters Into An Distribution Agreement With Juste
MediGene Enters Into Co-Development Agreement With Celltrion
MediGene Extends Collaboration Agreement With German Cancer Research Center
MediGene Enters Into Research Agreement With Juvenile Diabetes Research
MediGene Enters Into Research Agreement With Sanofi Pasteur
MediGene Enters Into Collaboration With German Cancer Research Center
MediGene Enters Into Co-Marketing Agreement With Bradley Pharmaceuticals
MediGene Enters Into Agreement With Yamanouchi
MediGene Enters Into Licensing Agreement With Virionics
MediGene Enters Into Licensing Agreement With Astellas Pharma
MediGene Enters Into Licensing Agreement With Pharmanova For Veregen
MediGene Enters Into Licensing Agreement With Syncore Biotechnology For Veregen
MediGene Enters Into Licensing Agreement With Triton Pharma For Veregen
MediGene Enters Into Licensing Agreement With Will-Pharma For Veregen
MediGene Enters Into Licensing Agreement With Pierre Fabre For Veregen
MediGene Enters Into Licensing Agreement With Laboratoires Expanscience
MediGene Enters Into License Agreement With GC-Rise Pharmaceutical
MediGene Enters Into Licensing Agreement With JS Bio Pharm
MediGene Signs Licensing Agreement With Meditrina Pharmaceuticals
MediGene Enters Into Licensing Agreement With Teva Pharmaceutical
MediGene Enters Into Licensing Agreement With Solvay Pharmaceuticals
MediGene Enters Into Licensing Agreement With German Cancer Research Center
MediGene Enters Into Licensing Agreement With Glaxo Group
Avidex Enters Into Licensing Agreement With Active Biotech
MediGene Enters Into Licensing Agreement With The University Of British Columbia
MediGene Enters Into Licensing Agreement With The University Of Chicago
MediGene Completes Private Placement Of $3 Million
MediGene Completes Private Placement Of $21 Million
MediGene Completes Private Placement Of $16 Million
MediGene Completes Private Placement Of $19 Million
MediGene Completes Private Placement Of $27 Million
MediGene Completes Private Placement Of $9 Million
MediGene Completes Private Placement Of $9 Million
MediGene Completes Private Placement Of 4% Convertible Bonds For $2 Million
MediGene Completes Sale Of European Rights For Eligard To Astellas
Catherex Acquires Oncolytic Herpes Simplex Viruses Program From MediGene
Galderma Laboratories Acquires Oracea Rights From MediGene
MediGene Acquires Avidex

List of Figures
MediGene AG – Pipeline by Therapy Area and Indication, H2 2011
MediGene AG – Pipeline by Stage of Development, H2 2011
MediGene AG – Pipeline By Therapeutic Class, H2 2011
MediGene AG - Pipeline By Target, H2 2011
MediGene AG – Pipeline By Route of Administration, H2 2011
MediGene AG – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• T-Mobile Germany: Mobile Broadband Case Study
• Steria
• HP - Profile - Germany
• Logica - Profile - Germany
• SAP - Profile - Germany
• Germany - Siemens IT Solutions and Services - Company Profile
• Germany - ESG - Company Profile
• Germany - Microsoft - Company Profile
• Germany - msg - Company Profile
• Germany - Wincor Nixdorf - Company Profile